glp-1 indigestion from Injections GLP-1 | Summary

Description

These medications mimic the actions of the endogenous incretin hormone GLP-1 by enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety.[1] Incretin hormones also exert effects across multiple organ systems, including cardiovascular, renal, and skeletal systems.[1] Owing to these pleiotropic mechanisms, the clinical use of GLP-1RAs has expanded exponentially, both for diabetes and for a broadening spectrum of diseases and conditions.[2] Obesity plays a central role in the pathogenesis and progression of T2DM, yet many traditional glucose-lowering therapies are associated with weight gain.[3] The observation that GLP-1RAs not only improve glycemic control but also result in significant weight loss marked a paradigm shift in diabetes pharmacotherapy, prompting investigation into their therapeutic potential in individuals without diabetes to treat obesity and related comorbidities.[4] Subsequently, large-scale cardiovascular and kidney outcome trials have demonstrated additional benefits of GLP-1RAs, further supporting their use in high-risk populations independent of diabetes status.[4] These trials resulted in a rapid evolution of the clinical landscape for GLP-1RAs in the last decade, with growing evidence supporting their role in treating obesity, cardiovascular disease, chronic kidney disease (CKD), and other metabolic-related disorders.[520] This expansion reflects both their favorable efficacy profile and their broader physiological effects

(30) Magruder et al

When their son Teddy brought that dream to Scottsdale, the restaurant quickly became a neighborhood fixture, celebrated for its fiery green chile, unfussy hospitality, and the unmistakable comfort of a home-cooked meal

Jonathan Kaplan MD, MPH, CEO of BuildMyHealth explains, Semaglutide mimics the natural incretin hormone GLP1, and sets off a cascade of physiological effects on insulin secretion, glucagon suppression, and appetite regulation by both peripheral and central nervous system mechanisms

Heres how its different from previous meds: Retatrutide is a triple agonist, meaning it targets three different hormone receptors, rather than one (like Ozempic) or two (like Mounjaro or Zepbound)